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Objective: To explore the protective effect and its molecular mechanism of apoptosis
signal-regulating kinase 1 (ASK1) inhibitor (GS-459679) on acetaminophen-induced
liver injury in mice.
Methods: The model of liver injury was established by administration of acetaminophen
(APAP) (300 mg/kg, i.p.) on C57BL/6 mice. Forty-eight male C57BL/6 mice were
randomly divided into four groups, consisting of control group, GS group (GS-459679,
30 mg/kg, i.p.), APAP-induced group, and GS combined with APAP-induced group. For
GS combined with APAP-induced group, mice were treated with GS 30 min prior to
administration of APAP. After mice were euthanized at 6 h or 12 h, respectively, serum
levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were
analyzed, and mRNA levels of TNF-a, IL-6 and IL-1b were tested. The activity of
glutathione (GSH), oxidized GSH (GSSG) and malondialdehyde were quantiﬁed. In
addition, ASK1, P-ASK1, JNK and P-JNK protein levels were tested in all groups.
Results: The ASK1 and P-ASK1 levels were up-regulated in APAP-induced group.
Compared to the control group, serum levels of ALT and AST, and mRNA levels of
TNF-a, IL-6 and IL-1b were increased in APAP-induced group. Meanwhile, the levels of
MAD and GSSG, and the ratio of GSSG/GSH were higher and the JNK was activatedin
APAP-induced group compared with that in control group. However, compared to
APAP-induced group, GS combined with APAP-induced group displayed a decrease of
protein expression levels of ASK1, P-ASK1 and P-JNK, a reduction of serum levels of
ALT and AST, a decrease in TNF-a, IL-6 and IL-1b mRNA levels, and a low ration of
GSSG/GSH.
Conclusions: GS-459679 treatment effectively down-regulates ASK1 and P-ASK1
expression. Addition of GS-459679 decreases the generation of liver metabolites and
inﬂammatory factors, reduces oxidative stress reaction, inhibits JNK activation, and then
protects the responsiveness to APAP-induced liver injury.1. Introduction
In recent years, drug-induced liver injury has become an
important factor affecting the treatment effect and prognosis of
patients in clinic, with paracetamol [acetaminophen (APAP)]induced liver injury as a typical representative [1–4]. High doses
or frequent cumulative use of APAP can induce acute and severe
liver tissue necrosis, and even cause liver failure and death.
APAP-induced liver injury is mainly due to that metabolism
of cytochrome P450 enzyme system produces excessive N-
acetyl-p-benzo-quinone imine (NAPQI), leading to peroxidatic
reaction of hepatic cellular mitochondrion eventually inducing
the activation of MAP and JNK signal path [5,6], thus causing
cell apoptosis or necrosis. Meanwhile, APAP activates the
body's immune cells to produce inﬂammatory factors, thus
activating immune system [2,7–10]. Therefore, to explore the
molecular mechanism of APAP-induced liver injury and ﬁnd
inhibiting effect of APAP-induced liver injury will provide anle under the CC BY-NC-ND license
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APAP-induced liver injury.
Apoptosis signal-regulating kinase 1 (ASK1) is one of the
family members of mitogen-activated protein kinase. Multiple
inﬂammatory factors and oxidative stress can activate ASK1 and
its Ser-83 and Thr-845 phosphorylation. Activated ASK1 in-
duces the activation of JKN downstream signaling pathways
through MKK3 and MKK4 [11], and ﬁnally leads to cell
apoptosis by caspase 3 pathway [12,13]. Nakagawa et al. found
that the APAP-induced liver injury was decreased in ASK1
knockout mice through inhibiting JNK pathway activation,
reducing serum level of alanine aminotransferase (ALT) and
oxidative stress level and decreasing the numbers of APAP-
induced liver cell apoptosis [9]. Xie et al. reported that
pretreatment of ASK1 inhibitor (GS-459679) lowered APAP-
induced peroxide stress of cellular mitochondria and inhibited
mitochondrial JNK activation [14]. However, the defensive
function of ASK1 inhibitor on APAP-induced liver injury is
still unclear. The present study aimed to discuss the protective
effect of GS-459679 on APAP-induced liver injury and the
preliminary research of its mechanism, which will provide new
drug molecules for the exploitation of treatment of APAP-
induced liver injury.
2. Materials and methods
2.1. Materials
Forty-eight male C57/BL6 mice of clean grade, aged 8 weeks
and weighted 20–25 g were purchased from Laboratory Animal
Centre of Nanjing University. GS-459679 (ASK1 inhibitor) was
bought from Gilead Sciences, Inc. Anti-bodies of ASK1, P-
ASK1, JNK1 and P-JNK were all purchased from Abcam.
cDNA reverse transcription kit (PrimeScript 1st Strand cDNA
Synthesis Kit) and ﬂuorescence quantitative PCR kit (SYBR
Green PCR Master Mix Kit) were bought from Takara Bio.
Protein lysis buffer (RIPA) and protein quantitative kit were
purchased from Thermo Fish. Glutathione (GSH) and malon-
dialdehyde (MAD) assay kit were bought from Beyotime.
2.2. Methods
2.2.1. Acute liver injury model
Forty-eight male C57/BL6 mice were randomly divided into
four groups (12 mice in each group), consisting of control group,
GS group (GS-459679), APAP-induced group, and GS combined
with APAP-induced group. Animals were fasting for 12 h before
experiment and water ad libitum. Mice in control group were
given intraperitoneal injection of PBS. GS group was treated with
30 mg/kg GS-459679 dissolved in PBS. In APAP-induced
group, 300 mg/kg APAP was injected intraperitoneally. For GS
combined with APAP-induced group, mice were treated with GS
30 min prior to administration of APAP. After administration of
6 h or 12 h, all the animals were sacriﬁced (3 mice each time).
Blood was collected and livers were separated. Various indexes
were detected to estimate the liver injury status. All the animal
experiments complied with the animal ethics standards.
2.2.2. Effects on biochemical index
Blood was collected from eyeball of mice in all groups. After
coagulation and keeping for 30 min, it was centrifuged at3000 rpm/min, 4 C for 15–20 min. Precipitation was discarded
and supernatant was taken. Contents of ALT and aspartate
aminotransferase (AST) were determined through 7170A auto-
matic biochemical analyzer. Liver tissues were taken to make
into homogenate, and contents of GSH, oxidized GSH (GSSG)
and MDA were tested according to kit instructions. MDA con-
tent was detected according to the MAD kit operational
procedure.
2.2.3. Q-PCR method
Mice in all the groups were sacriﬁced under anesthesia. Livers
were separated, and 50–100 mg liver issues were made into ho-
mogenate. Total RNA was extracted by phenol chloroform
extracting method as follows: 1 mL Trizol was added in liver
issue and kept for 50 min, and then 200 mL chloroform was added
and mixed to stand for 10 min; after centrifugation at 10000 rpm/
min, 4 C for 10 min, upper water phase was taken to add 1-fold
volume of isopropyl alcohol and keep for 10 min; after centri-
fugation at 4 C for 10 min, supernatant was discarded, and
precipitation was washed with 75% ethanol and dried at room
temperature. The extracted RNA was reversed to cDNA by two
steps method according to the kit instruction, and the concen-
tration of cDNA was detected by UV spectrophotometer. TNF-a
primer sequence: forward primer: GACGTGGAACTGGCA-
GAAGAG, reverse primer: TTGGTGGTTTGTGAGTGTGAG;
IL-6 primer sequence: forward primer: CCAA-
GAGGTGAGTGCTTCCC, reverse primer: CTGTTGTTCA-
GACTCTCTCCCT; IL – 1b primer sequence: Forward primer:
GCAACTGTTCCTGAACTCAACT, reverse primer:
ATCTTTTGGGGTCCGTCAACT. GAPDH was considered as
internal reference. GAPDH primer sequence: forward primer:
AGGTCGGTGTGAACGGATTTG, reverse primer: TGTA-
GACCATGTAGTTGAGGTCA. After standardization of cDNA,
Q-PCR reaction system ampliﬁcation was as follow: pre degen-
eration at 94 C for 5 min, degeneration at 94 C for 30 s, anneal
at 65 C for 50 s, extension at 72 C for 1 min, 30 cycles;
extension at 70 C for 10 min. mRNA levels of TNF-a, IL-6 and
IL-1b were detected by ABI 7900 HT Fast software.
2.2.4. Western blot method
About 100–200 g liver issue was taken and pyrolyzed by
RIPA. After centrifugation at 12000 rpm/min, 4 C for 10 min,
supernatant was obtained. Total protein content was acquired
according to protein quantitative kit steps. A total of 40–60 mg
protein was taken to perform SDS-PAGE electrophoresis,
transmembrane, sealing, hatching primary antibodies (anti-
ASK1, 1:1500; anti-P-ASK1, 1:1000; anti-JNK, 1:2000; anti-P-
JNK, 1:1000; anti-ASK1, 1:1500; anti-P-ASK1, 1:1000; anti-
JNK, 1:2000; anti-P-JNK, 1:1000), washing, hatching second
antibodies and developing, expression levels of ASK1, P-ASK1,
JNK and P-JNK were detected. GAPDH was the internal
reference.
2.3. Statistical analysis
All the data were processed with Graphpad prism 5.0. Data
were expressed as mean ± SEM. t-test was used for the com-
parisons of ALT, AST, GSH, GSSD levels and mRNA levels of
TNF-a, IL-6 and IL-1b between APAP-induced group and GS
combined with APAP-induced group. P < 0.05 was considered
as statistically signiﬁcant.
Table 4
Effects of ASK1 inhibitor on the mRNA levels of TNF-a, IL-6 and IL-1b
in the mice of APAP-induced liver injury [n (Repeat Count) = 3].
Group TNF-a IL-6 IL-1b
Control group 1.029 ± 0.135 0.674 ± 0.147 1.062 ± 0.171
GS group 0.923 ± 0.065 0.940 ± 0.162 0.932 ± 0.264
APAP-induced group 3.941 ± 0.503 2.091 ± 0.416 7.281 ± 1.047
GS + APAP-induced
group
2.654 ± 0.462 1.325 ± 0.247 3.262 ± 0.403
P-value1 0.001 0.005 0.001
P-value2 0.031 0.052 0.003
P-value1: APAP-induced group compared with control; P-value2:
GS + APAP-induced group compared with APAP-induced group.
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3.1. Effects of APAP-induced liver injury on ASK1
expression
As shown in Table 1, through western blot test, expression
level of ASK1 and P-ASK1 in APAP-induced liver injury group
increased; at the same time, GS-459679 signiﬁcantly decreased
the protein levels of ASK1 and P-ASK1, which was consistent
with the previous report [9]. Hence, GS-459679 could be used as
an effective ASK1 inhibitor.
3.2. Effects of ASK1 inhibitor on serums of ALT and AST
Compared to control group, after 12 h of APAP-induced liver
injury, levels of ALT and AST increased signiﬁcantly, while
those in GS combined with APAP-induced group and APAP-
induced group after 12 h of administration signiﬁcantly
decreased (ALT: P < 0.05; AST: P < 0.05) (Table 2).Table 1
Inhibition of ASK1 and P-ASK1 levels by addition of GS-459679 [n





Control group 0.233 ± 0.080 0.199 ± 0.056
GS group 0.145 ± 0.058 0.153 ± 0.047
APAP-induced group 0.611 ± 0.095 0.546 ± 0.078
GS + APAP-induced
group
0.349 ± 0.070 0.374 ± 0.066
P-value1 0.002 0.003
P-value2 0.018 0.043
P-value1: APAP-induced group compared with control; P-value2:
GS + APAP-induced group compared with APAP-induced group.
Table 2
Effects of ASK1 inhibitor on serum ALT and AST levels in the mice of
APAP-induced liver injury [n (repeat count) = 3].
Group ALT (U/L) AST (U/L)
Control group 75.00 ± 15.00 70.67 ± 9.50
GS group 71.67 ± 14.57 61.33 ± 11.02
APAP-induced group 1860.00 ± 263.62 2313.34 ± 339.38
GS + APAP-induced group 1016.00 ± 218.58 1632.33 ± 213.89
P-value1 0.001 0.000
P-value2 0.013 0.042
P-value1: APAP-induced group compared with control; P-value2:
GS + APAP-induced group compared with APAP-induced group.
Table 3
Effects of ASK1 inhibitor on the levels of GSH, GSSG and MAD in the mi
Group GSH (mmol/g) GSS
Control group 7.912 ± 1.901 2.50
GS group 7.946 ± 1.723 1.61
APAP-induced group 7.185 ± 1.185 3.57
GS + APAP-induced group 7.812 ± 1.126 2.87
P-value1 0.544 0.04
P-value2 0.515 0.17
P-value1: APAP-induced group compared with control; P-value2: GS + AP3.3. Effects of ASK1 inhibitor on the contents of GSH,
GSSG and MAD
As shown in Table 3, compared to normal control group,
after 12 h of APAP induction, GSH level changed, GSSG level
increased (P < 0.05), GSSG/GSH ratio increased signiﬁcantly
(P < 0.05), and MAD level increased (P < 0.05). In GS com-
bined with APAP-induced group, compared to APAP-induced
group, there were no signiﬁcant difference in terms of GSH,
GSSG and MAD levels; at the same time, GSSG/GSH ratio
recovered signiﬁcantly (P < 0.05). The results showed that
ASK1 decreased the APAP-induced oxidative stress level.
3.4. Effects of ASK1 inhibitor on the mRNA level of
inﬂammatory factors
Q-PCR detection showed that compared to control group
(Table 4), the mRNA levels of TNF-a, IL-6 and IL-1b were
signiﬁcantly increased after 6 h of APAP induction (TNF-a:
P < 0.01; IL-6: P < 0.01; IL-1b: P < 0.01). Compared to APAP-
induced group, the mRNA levels of TNF-aand IL-1b in GS
combined with APAP-induced group were signiﬁcantly
decreased (TNF-a: P < 0.05; IL-1b: P < 0.01), but were higher
than those in control group. But, there was no signiﬁcant dif-
ferences in mRNA levels of IL-6 (P = 0.052). Therefore, the
decrease of ASK1 inhibitor was produced by APAP-induced
inﬂammatory factors.
3.5. Effects of ASK1 inhibitor on JNK expression level
Table 5 showed that P-JNK level in GS group was slightly
lower than that in control group, and it was higher in APAP-
induced group compared to that in control group. However, P-
JNK level in GS combined with APAP-induced group was
signiﬁcantly lower than that in APAP-induced group, but wasce of APAP-induced liver injury [n (repeat count) = 3].
G (mmol/g) GSSG/GSH (%) MAD (mmol/g)
4 ± 0.657 0.316 ± 0.031 0.077 ± 0.075
1 ± 0.313 0.203 ± 0.036 0.071 ± 0.082
6 ± 0.778 0.498 ± 0.091 0.924 ± 0.523
5 ± 0.692 0.338 ± 0.031 0.323 ± 0.231
6 0.031 0.050
1 0.045 0.143
AP-induced group compared with APAP-induced group.
Table 5
Effects of ASK1 inhibitor on protein levels of JNK and P-JNK in the mice





Control group 0.160 ± 0.029 0.930 ± 0.105
GS group 0.079 ± 0.062 0.943 ± 0.095
APAP-induced group 0.945 ± 0.110 0.878 ± 0.058
GS + APAP-induced
group
0.608 ± 0.116 0.896 ± 0.076
P-value1 0.000 0.495
P-value2 0.016 0.761
P-value1: APAP-induced group compared with control; P-value2:
GS + APAP-induced group compared with APAP-induced group.
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niﬁcant differences in JNK expression levels among control,
APAP-induced and GS combined with APAP-induced groups.
The results showed that ASK1 inhibitor decreased the phos-
phorylation of JNK. What's more, ASK1 inhibitor signiﬁcantly
decreased the JNK activation which was caused by APAP
induction.
4. Discussion
ASK1 is serine/threonine-protein kinase, which activates P38
and JNK molecule through MAPK pathway activation [15].
Under resting state, thioredoxin (Trx) bonded the N-terminal
domains of ASK1 to form Trx-ASK1 compound, thus inhibit-
ing ASK1 activation. Under the external stimulation (such as
oxidative stress and inﬂammatory factors), Trx and ASK1 were
separated to cause ASK1 activation, thus inducing the MAP2
phosphorylation and downstream JNK activation [9,16]. Study of
Nakagawa et al. showed that ASK1−/− mice effectively protect
APAP-induced liver injury through inhibiting JNK activation [9].
Xie et al. found that pretreatment of ASK1 inhibitor (GS-
459679) lowered APAP-induced peroxide stress of cellular
mitochondria and inhibited mitochondrial JNK activation [14].
On the basis of the result, the present study further illuminated
the mechanism of effect of ASK1 inhibitor on APAP-induced
liver injury. Our study showed that GS-459679 can decrease
the APAP-induced serum transaminase levels (ALT and AST),
reduce oxidative stress product (GSSG), inhibit the expressions
of inﬂammatory factors (TNF-a, IL-6 and IL-1b), and JNK
activation, and thus protect APAP-induced liver injury.
When excessive APAP is ingested, most of the drugs are
combine with glucuronic acid and expelled from the body, while
a small part of drugs generate NAPQI by oxidation reaction of
cytochrome P450 enzyme system; after exhausting GSH,
NAPQI is combined with sulfhydryl-containing proteins, thus
causing oxidative stress and dysfunction of mitochondria and
ﬁnally inducing a function of liver cells [7,8,17,18]. Hence,
inhibition of oxidative stress is the key to protect APAP-
induced liver injury. It was found that the oxidant and antioxi-
dant balance (GSSG/GSH) of liver cells was broken in APAP-
induced liver injury. After the pretreatment of ASK1 inhibitor,
GSSG level and GSSG/GSH ratio were decreased, that is to say,
the balance of the redox reaction of liver cells got certain re-
covery. Hyun also reported that ASK1 inhibitor can decrease the
ROS level of liver cells, reduce the output of lipid oxidation
products and inhibit oxidative stress [19].Many literatures reported that APAP-induced liver cell
apoptosis and necrosis can further activate immune cells such as
NK and neutrophile granulocyte which secrete a variety of in-
ﬂammatory factors, and then accelerate the failure of liver
function [9,10,20]. Nakagawa et al. reported that in APAP-
induced liver injury model of ASK1−/− mice, expression
levels of IL-1a and IL-1b were all reduced [9]. It is found in our
study that compared to APAP-induced group, TNF-a, IL-6 and
IL-1b in GS combined with APAP-induced group decreased by
different degrees, which indicated that ASK1 inhibitor can also
reduce products of inﬂammatory factors and lower the body's
immune response.
Mitochondrial oxidative stress in APAP-induced liver injury
eventually activates JNK pathway induced liver cell apoptosis or
necrosis [5]. ASK1 is the upstream signal molecule of JNK,
which can activate JNK into the nucleus by the activation of
MKK3 and MKK4, thus causing apoptosis [11]. Hayakawa
et al. reported that ASK1 inhibitor (K188) decreased the
proliferation and tumor size of gastric carcinoma cells through
inhibiting JNK phosphorylation [12]. Xie et al. found that GS-
459679 reduced the JNK activator positioning of mitochon-
dria, and GS-459679 protected APAP-induced liver injury
through inhibiting JNK pathway [14]. Our study also showed that
GS-459679 inhibited JNK phosphorylation, which further il-
lustrates that the protective effect of ASK1 inhibitor on APAP-
induced liver injury depends on activation inhibition of JNK.
In conclusion, ASK1 inhibitor (GS-459679) can protect the
APAP-induced liver injury through eliminating toxic metabolite
of liver, inhibiting oxidative stress, removing immune response
and inhibiting JNK activation at the molecular level. However,
the therapeutical effect of GS-459679 still needs to be further
conﬁrmed, and therapeutic window of GS-459679 use needs to
be intensively studied.
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